联合检测MA、BUN、sCr、eGFR在他克莫司致移植肾早期损伤发生中的诊断价值

王浩; 赖大海; 黄帅帅; 金爱慧; 许沉龙; 岑东

doi:10.16766/j.cnki.issn.1674-4152.003430

联合检测MA、BUN、sCr、eGFR在他克莫司致移植肾早期损伤发生中的诊断价值

doi: 10.16766/j.cnki.issn.1674-4152.003430

1.
宁波市泌尿肾病医院检验科，浙江宁波 315100
2.
宁波市泌尿肾病医院肾病研究所

基金项目:

浙江省卫生健康科技计划项目 2022KY1177

宁波市自然科学基金项目 2023J233

详细信息

通讯作者:
岑东，E-mail: cendong2002@163.com

中图分类号: R446.11 R692
计量
- 文章访问数: 223
- HTML全文浏览量: 68
- PDF下载量: 14
- 被引次数: 0
出版历程
- 收稿日期: 2023-11-29
- 网络出版日期: 2024-05-27

Application of combined detection of MA, BUN, sCr and eGFR in early renal graft injury induced by tacrolimus

1.
Department of Clinical Labortary, Ningbo Hospital of Urinary Nephropathy, Ningbo, Zhejiang 315100, China

摘要

摘要: 目的联合检测尿微量白蛋白(MA)、血尿素氮(BUN)、血肌酐(sCr)和估算的肾小球滤过率(eGFR)在评估肾移植后患者因使用他克莫司(Tac)所致的移植肾功能损伤早期发现的临床价值。方法选取2015年8月—2020年7月宁波市泌尿肾病医院收治的长期使用Tac的肾移植患者54例，同一患者根据Tac持续使用的时间分为12个月组(A组)、24个月组(B组)进行比较分析，以评估MA、BUN、sCr、eGFR以及联合检测的临床价值。结果比较发现，B组MA、eGFR较A组差异均有统计学意义(P＜0.05)，但BUN、sCr组间差异均无统计学意义(P＞0.05)。eGFR与MA、BUN、sCr均呈负相关关系[用药12个月组(A组)和用药24个月(B组)r值分别为-0.413、-0.538、-0.797(P＜0.01)和-0.333、-0.647、-0.738(P＜0.05)]，且与Tac持续使用时间具有相关性，在移植后早期相关性更为显著。受试者工作特征曲线显示，MA、BUN、sCr、eGFR单独检测的AUC分别为0.680、0.594、0.581、0.689，4项指标联合检测时AUC为0.839。结论 MA、BUN、sCr、eGFR四项肾功能损伤标志物联合检测对肾移植后持续使用Tac患者肾功能损伤的发生具有早期诊断价值。
- 肾移植 /
- 肾功能损伤 /
- 他克莫司 /
- 标志物 /
- 联合检测
Abstract: Objective To assess the clinical value of early detection of the risk of graft dysfunction in post-renal transplant patients after continued use of tacrolimus (Tac) by combined detection of urinary microalbumin (MA), blood urea nitrogen (BUN), serum creatinine (sCr) and estimated glomerular filtration rate (eGFR). Methods Fifty-four renal transplant patients who had been using Tac for a long time and were admitted to Ningbo Hospital for urinary nephropathy between August 2015 and July 2020 were selected. The patients were divided into two groups: group A, which used Tac continuously for 12 months, and group B, which used Tac continuously for 24 months. The clinical value of MA, BUN, sCr, eGFR and combined detection were evaluated through comparative analysis. Results Compared to group A, group B showed significant differences in MA and eGFR (P < 0.05), but not in BUN and sCr (P > 0.05). There was a negative correlation between eGFR and MA, BUN and sCr [r values of 12 months (group A) and 24 months (group B) were-0.413, -0.538, -0.797 (P < 0.01) and -0.333, -0.647, -0.738 (P < 0.05), respectively], and was significantly correlated with Tac duration, particularly in the early post-transplantation period. Based on the receiver operating characteristic curve, the AUC for MA, BUN, sCr and eGFR individually were 0.680, 0.594, 0.581 and 0.689, respectively. The combined detection of the four indicators resulted in an AUC of 0.839. Conclusion The detection of four renal injury markers (MA, BUN, sCr and eGFR) can aid in the early diagnosis of renal insufficiency in patients who continue to use Tac after renal transplantation.
- Kidney transplant /
- Renal function impairment /
- Tacrolimus /
- Marker /
- Combined detection

HTML全文

图 1 肾移植术后持续使用不同时间Tac后患者eGFR的变化

Figure 1. Changes in eGFR at various time points following Tac use post renal transplantation

下载: 全尺寸图片幻灯片

图 2 MA、BUN、sCr、eGFR单独检测在肾移植后使用Tac导致肾功能损伤发生中的诊断价值

Figure 2. The diagnostic value of MA, BUN, sCr, and eGFR individually in Tac-induced renal injury post renal transplantation

下载: 全尺寸图片幻灯片

图 3 四项指标联合检测在肾移植后使用Tac导致肾功能损伤发生中的诊断价值

Figure 3. The combined diagnostic value of the four indicators in Tac-induced renal injury post renal transplantation

下载: 全尺寸图片幻灯片

表 1 持续使用Tac的肾移植患者MA、BUN、sCr、eGFR水平的变化[M(P₂₅, P₇₅)]

Table 1. Changes in MA, BUN, sCr and eGFR levels in renal transplant patients on continuous Tac use[M(P₂₅, P₇₅)]

组别	例数	MA(mg/L)	BUN(mmol/L)	sCr(μmol/L)	eGFR[mL/(min·1.73 m²)]	bTac(ng/mL)
A组	54	8.75(3.93，17.88)	6.31(5.32，7.09)	95.95(82.65，105.70)	92.0(78.0，97.0)	6.10(4.85，6.90)
B组	54	17.35(7.43，52.05)	6.81(5.94，7.19)	100.50(81.25，114.75)	74.0(61.5，91.0)	5.60(4.93，6.28)
V值		62.000	568.000	528.500	1 328.500	927.500
P值		＜0.001	0.134	0.066	＜0.001	0.112

下载: 导出CSV

参考文献(20)

[1]	LAI X Q, ZHENG X, MATHEW J M, et al. Tackling chronic kidney transplant rejection: challenges and promises[J]. Front Immunol, 2021, 12: 661643. DOI: 10.3389/fimmu.2021.661643.
[2]	BAUER A C, FRANCO R F, MANFRO R C. Immunosuppression in kidney transplantation: state of the art and current protocols[J]. Curr Pharm Des, 2020, 26(28): 3440-3450. doi: 10.2174/1381612826666200521142448
[3]	BANAS B, KRǍMER B K, KRÜGER B, et al. Long-term kidney transplant outcomes: role of prolonged-release tacrolimus[J]. Transplant Proc, 2020, 52(1): 102-110. doi: 10.1016/j.transproceed.2019.11.003
[4]	TOWNAMCHAI N, AVIHINGSANON Y. Updated management for antibody-mediated rejection: opportunity to prolong kidney allograft survival[J]. Curr Opin Nephrol Hypertens, 2023, 32(1): 13-19. doi: 10.1097/MNH.0000000000000843
[5]	RONG Y, MAYO P, ENSOM M H H, et al. Population pharmacokinetics of mycophenolic acid Co-administered with tacrolimus in corticosteroid-free adult kidney transplant patients[J]. Clin Pharmacokinet, 2019, 58(11): 1483-1495. doi: 10.1007/s40262-019-00771-3
[6]	李圣冰, 陈文, 李修彬, 等. Multi-Latex多聚粒技术联合检测尿微量蛋白在肾移植术后无创诊断中的应用价值[J]. 器官移植, 2020, 11(4): 443-448. doi: 10.3969/j.issn.1674-7445.2020.04.003 LI S B, CHEN W, LI X B, et al. Application value of Multi-Latex technique combined with detection of urinary microprotein in non-invasive diagnosis of renal transplantation[J]. Organ transplantation, 2020, 11(4): 443-448. doi: 10.3969/j.issn.1674-7445.2020.04.003
[7]	WEINGART C, WIRNSBERGER G H. Clinical implications of the estimated glomerular filtration rate[J]. Z Gerontol Geriatr, 2021, 54(3): 205-210. doi: 10.1007/s00391-021-01839-1
[8]	SHI B Y, YUAN M. Guidelines for the treatment of immunosuppression in Chinese kidney transplant recipients[J]. Organ transplantation, 2016, 7(5): 327-331. doi: 10.3969/j.issn.1674-7445.2016.05.001
[9]	王学晶. 临床实验室应关注估算肾小球滤过率的报告[J]. 中华检验医学杂志, 2016, 39(12): 888-891. doi: 10.3760/cma.j.issn.1009-9158.2016.12.005 WANG X J. Clinical laboratory should pay attention to the report of estimated glomerular filtration rate[J]. Chin J Lab Med, 2016, 39(12): 888-891. doi: 10.3760/cma.j.issn.1009-9158.2016.12.005
[10]	MǍRUNTELU I, NISTOR C E, CRISTEA B M, et al. Retrospective study from a single center in Romania of 347 renal transplant patients treated with tacrolimus, mycophenolate, and steroids to evaluate the association between anti-HLA antibodies and 5-year graft survival[J]. Ann Transplant, 2022, 27: e937267. DOI: 10.12659/AOT.937267.
[11]	XUE W J, TIAN P X, XIANG H L, et al. Outcomes for primary kidney transplantation from donation after citizens death in China: a single center experience of 367 cases[J]. BMC Health Serv Res, 2017, 17(1): 250. doi: 10.1186/s12913-017-2190-7
[12]	SENEV A, COEMANS M, LERUT E, et al. Eplet mismatch load and De novo occurrence of donor-specific anti-HLA antibodies, rejection, and graft failure after kidney transplantation: an observational cohort study[J]. J Am Soc Nephrol, 2020, 31(9): 2193-2204. doi: 10.1681/ASN.2020010019
[13]	KOROGIANNOU M, ALEXANDROU M E, SARAFIDIS P, et al. Sex-related short-term blood pressure variability differences in kidney transplant recipients[J]. Blood Press Monit, 2022, 27(6): 371-377. doi: 10.1097/MBP.0000000000000621
[14]	李泉源, 严礼琴, 魏涧, 等. 肾移植术后出现严重感染的原因及转归分析[J]. 中华全科医学, 2018, 16(6): 889-891. doi: 10.16766/j.cnki.issn.1674-4152.000243 LI Q Y, YAN L Q, WEI J, et al. The reasons for serious infections and outcome analysis after renal transplantation[J]. Chinese Journal of General Practice, 2018, 16(6): 889-891. doi: 10.16766/j.cnki.issn.1674-4152.000243
[15]	BENTATA Y. Tacrolimus: 20 years of use in adult kidney transplantation[J]. Artif Organs, 2020, 44(2): 140-152. doi: 10.1111/aor.13551
[16]	CHEUNG C Y, TANG S C W. Personalized immunosuppression after kidney transplantation[J]. Nephrology, 2022, 27(6): 475-483. doi: 10.1111/nep.14035
[17]	MACIEL N B, SCHWAMBACH K H, BLATT C R. Liver Transplantation: tacrolimus blood levels variation and survival, rejection and death outcome[J]. Arq Gastroenterol, 2021, 58(3): 370-376. doi: 10.1590/s0004-2803.202100000-62
[18]	ONG S C, GASTON R S. Thirty years of tacrolimus in clinical practice[J]. Transplantation, 2021, 105(3): 484-495. doi: 10.1097/TP.0000000000003350
[19]	ZHANG L, ZHANG T J, LI Y, et al. Shenqi Yanshen formula (SQYSF) protects against chronic kidney disease by modulating gut microbiota[J]. Bioengineered, 2022, 13(3): 5625-5637. doi: 10.1080/21655979.2021.2023789
[20]	LASZCZYNSKA O, SEVERO M, MASCARENHAS J, et al. Serum creatinine trajectories in real-world hospitalized patients: clinical context and short-term mortality[J]. J Investig Med, 2020, 68(4): 870-881. doi: 10.1136/jim-2019-001185